Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Providing Genomic Testing for Pharmatech's Cancer Registry

NEW YORK (GenomeWeb) – Paradigm today announced it has initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

Non-profit diagnostics shop Paradigm offers a next-generation sequencing-based cancer test called PCDx that sequences both DNA and RNA. It will provide the test for patients that are enrolled in Pharmatech's AccessPPM, a cancer registry that collects electronic medical record data and genomic information to match cancer patients with targeted clinical trials.

"We believe AccessPPM will change the way today's oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research," Pharmatech CEO Rob Bohacs said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.